



## Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2014 Financial Results

March 3, 2015

BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 3, 2015-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2014, on Tuesday, March 10, 2015. Following distribution of the earnings release via wire services, the Ocular management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to review the Company's financial results and provide a business update.

The live webcast can be accessed by visiting the investor section of Ocular's website at [investors.ocutx.com](http://investors.ocutx.com). Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 844-464-3934 (U.S.) or 765-507-2620 (International) to listen to the conference call. The conference ID number for the live call will be 98833560. An archive of the webcast will be available until March 24, 2015 on the company's website.

### About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix's lead product candidates are in Phase 3 clinical development for post-surgical ocular inflammation and pain, and Phase 2 clinical development for glaucoma, allergic conjunctivitis, and dry eye disease. The Company is also evaluating sustained-release injectable anti-VEGF drug depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Source: Ocular Therapeutix, Inc.

#### Investors:

Ocular Therapeutix, Inc.

Brad Smith

Chief Financial Officer

[bsmith@ocutx.com](mailto:bsmith@ocutx.com)

or

Burns McClellan on behalf of Ocular Therapeutix

Kimberly Minarovich, 212-213-0006

[kminarovich@burnsmc.com](mailto:kminarovich@burnsmc.com)

or

#### Media:

Scott Corning

Vice President of Sales and Marketing

[scorning@ocutx.com](mailto:scorning@ocutx.com)